There were 1,264 press releases posted in the last 24 hours and 466,682 in the last 365 days.

Myriad to Announce Fiscal Second-Quarter 2016 Financial Results on February 2

SALT LAKE CITY, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, Feb. 2.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, chief financial officer, will provide an overview of Myriad’s financial performance for the fiscal second-quarter and provide a business update.

To listen to the call, interested parties in the United States may dial 800-676-1873 or +1 303-223-4378 for international callers.  All callers will be asked to reference reservation number 21802448. The conference call also will be available through a live webcast and a slide presentation pertaining to the earnings call will also be available under the investor section of our website at  A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 within the United States or +1 402-977-9140 for international callers and entering reservation number 21802448.

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where high value diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer markets, diversifying its product portfolio through the introduction of new products and increasing its international contribution.  For more information on how Myriad is making a difference, please visit the Company's website:  

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G


Media Contact: Ron Rogers 
(801) 584-3065

Investor Contact: Scott Gleason 
(801) 584-1143

Primary Logo